Good Morning Market Enthusiast,

We just talked about this name not long ago — and since then, it’s hit NIH funding, secured FDA Fast Track, and now just pulled in fresh capital to charge ahead with its Phase 2 cancer trial.

That’s not noise. That’s execution.

MAIA Biotechnology, Inc. (NYSE American: MAIA)  is a name you’ve seen before… but it’s evolving fast, and the market is taking notice again.

This is what momentum looks like when it starts with fundamentals.

Let’s rewind for a moment, because the recent string of events is stacking up like this: (11)(19)(21)(22)(23)

🗓️ July 28: Company secures FDA Fast Track designation for its lead compound, ateganosine (THIO).  
🗓️ Sept 24: MAIA announces a $2.3M grant from the National Institutes of Health (NIH) to fund U.S. enrollment in its THIO-101 trial.  
🗓️ Sept 29: Raises $2.25M in a private placement to fund the next step in the same trial.  
🗓️ Oct 13: Announces a further private placement of $736,600 to fund Step 1 of Part C of the Phase II THIO-101 trial.
🗓️ Oct 23: MAIA presents at ESMO 2025 in Berlin, highlighting new 30-month (912-day) survival in its ongoing Phase 2 THIO-101 trial for advanced non-small cell lung cancer (NSCLC). 

“A patient that began therapy in March 2023 has shown survival of 30 months — an outstanding measure in high-risk cancers with limited options,” said CEO Dr. Vlad Vitoc. “Very few options exist for patients refractory or resistant to immune checkpoint inhibitors. We believe this durable response is a clear signal of ateganosine’s potential to effectively target and eliminate tumor cells.” (23)

The ESMO update also showcased two posters — one on the Phase 2 THIO-101 trial and another on the Phase 3 THIO-104 study, placing MAIA’s technology in front of a global oncology audience and further validating its progression toward late-stage development. (23)

📊 Current chart setup: Pressing up toward the 200-day SMA (~$1.77) with support holding
🛟 Float: Just ~28.3M shares, leaving room for big moves
🎯 Analyst targets: One at $14 (700%+), another at $10.27 (500%+)

That’s a powerful combination — a technical squeeze forming around a fundamentally reinforced pipeline.

(20)

🔬 The Science Behind MAIA: Disrupting Telomeres to Kill Cancer

MAIA’s technology is rooted in a first-in-class small molecule therapy — ateganosine (also called THIO).

New data from ESMO 2025 reinforces this mechanism — showing a 30-month survivor in THIO-101 and confirming ateganosine’s ability to drive durable tumor regression even in ICI-resistant patients. (23)

What it does:

• Targets telomeres, the protective DNA caps that help cancer cells replicate endlessly
• It also re-sensitizes tumors to immune attack — making immunotherapies work again in patients who previously stopped responding

This is especially relevant for advanced non-small cell lung cancer (NSCLC) — a high-mortality cancer with limited options once frontline chemo and checkpoint inhibitors fail.

🔒 Funding locked: $2.25M (Sept 29) + $736.6K (Oct 13) for THIO-101 Step 1 (21)(22)

Here’s the fresh development:

MAIA recently announced a private placement of ~1,733,766 shares at $1.30 each (with warrants at $1.57 exercisable in 6 months, valid for 3 years) to raise approx $2.25 M — the proceeds earmarked to fund Step 1 of Part C in its Phase II THIO-101 trial.  

Shares priced at $1.30, alongside warrants at $1.57

Warrants are exercisable in six months and last for 3 years

One participant is a company director — signaling internal confidence

This raise didn’t come cheap — and it didn’t come from tourists. It’s a strong sign that MAIA intends to accelerate, not wait.

And with the chart moving right around the raise price, momentum chasers are watching closely.

🧬 NIH Co-Sign + FDA Fast Track = Major De-Risking

This isn’t just a pipeline story anymore — it’s a story with federal and regulatory validation.

• Sept 24: $2.3M Grant from NIH — backs U.S. patient enrollment in the THIO-101 trial. (19)
• July 28: FDA Fast Track Status Secured — Fast Track designation from the FDA reflects serious potential. (11) 

“If approved, ateganosine would have a first-to-market competitive position… with a potential FDA decision as early as next year.” — CEO Dr. Vlad Vitoc (from earlier article context)

📊 Analyst Targets Are Sky High

Robert LeBoyer @ Noble Life Science Partners 

Target: $14.00

Rationale: Multiple checkpoint inhibitor partnerships (including Roche), improved OS and PFS, and favorable safety data

Diamond Equity Research 

Target: $10.27

Cites: 17.8-month median survival in Phase 2, strong durability, and Fast Track designation

Those targets imply 500%–700%+ upside from recent levels.

⚙️ Trial Progress + Next Steps Are Clear

With both NIH and private funding now secured, MAIA is moving into the execution phase of its THIO-101 trial:

• Step 1 of Part C now funded and launching
• U.S. patient enrollment greenlit
• Pivotal Phase II THIO-104 on deck for 2H 2025
• Accelerated approval possible in 2026, contingent on THIO-101 outcomes

This is a high-conviction roadmap backed by government money, regulatory clearance, and now capital to move forward without delay.

📊 Low Float + Breakout Setup

Float: ~28.3M shares

Chart: Pressing into multi-month resistance with 200-day SMA near ~$1.77

Support: Holding prior lows and building higher

When technical momentum meets fresh catalysts, the setup can flip fast.

🔁 The Big Picture: We’ve Been Here Before

MAIA isn’t a stranger to breakout setups.

It’s back — but this time, it’s:

• Better funded
• Further along in its trial
• Backed by NIH
• Fast-tracked by the FDA
• Building new partnerships
• And attracting renewed attention from the Street

This isn’t just a repeat. It could be bigger.

We’ve talked about MAIA Biotechnology, Inc. (NYSE American: MAIA) before. But what’s happening now feels like the next act — and all the signals are starting to sync again.

Stay alert. I’ll keep you updated as it unfolds.

To your success,

Max Masters

Co-founder, Market Tips Newsletter

Sources:
1. https://bit.ly/4cLWaog

2. https://bit.ly/4cRuZZk

3. https://bit.ly/42pGNOM

4. https://bit.ly/4cVjJLl

5. https://bit.ly/4jmedDM

6. https://finance.yahoo.com/quote/MAIA/history/
7. https://bit.ly/4lKdluq
8. https://bit.ly/3GminNn

9. https://finance.yahoo.com/news/maia-biotechnology-announces-first-patient-131500434.html
10. https://finance.yahoo.com/news/maia-biotechnology-announces-peer-reviewed-131700117.html
11. https://finance.yahoo.com/news/maia-biotechnology-receives-fda-fast-120100331.html
12. https://finance.yahoo.com/news/maia-biotechnology-granted-european-patent-130100345.html

13. https://finance.yahoo.com/news/diamond-equity-research-releases-note-120000909.html

14. https://ml.globenewswire.com/Resource/Download/b5e1fff3-02a0-4a78-b533-2ec8845f612e

15. https://finance.yahoo.com/news/maia-biotechnology-announces-publication-interim-130100253.html
16. https://finance.yahoo.com/news/maia-biotechnology-abstract-selected-poster-130300068.html

17. https://maiabiotech.com/
18. https://ir.maiabiotech.com/company-information/presentations
19. https://finance.yahoo.com/news/maia-biotechnology-awarded-2-3-120100527.html
20.  https://ir.maiabiotech.com/
21. https://finance.yahoo.com/news/maia-biotechnology-announces-2-25-203000956.html
22. https://finance.yahoo.com/news/maia-biotechnology-announces-736-600-202000357.html
23. https://finance.yahoo.com/news/maia-biotechnology-details-30-month-123600465.html

Momentum Media LLC has not been compensated for today's profile on MAIA Biotechnology Inc. (MAIA:US). Momentum Media LLC has been previously hired for a period beginning on 10/26/2025 and ending on 10/27/2025 (the “Campaign”) to publicly disseminate information about MAIA Biotechnology Inc. (MAIA:US). Momentum Media LLC has been compensated $10,000.00 and are owed an additional $0 for the Campaign. To date, we have been paid $79,600.00. Please read Momentum Media LLC’s complete disclaimer at https://markettips.net/disclaimer/ which includes important information. Emojis, graphics and/or images used herein have no specific or implied meaning, and are used for artistic purposes only. Nothing contained herein is financial advice. Momentum Media LLC is not an analyst, st.o.ck broker, financial adviser or st.o.ck picker nor is it qualified to act in the capacity of any of the foregoing. Information herein is a paid advertisement and should not be relied upon as accurate or complete.